Skip to Main Content
Contribute Try STAT+ Today

WASHINGTON — Democrats in Congress are already gearing up for their next big legislative push, and drug pricing reforms will be a tempting piggy bank to pay for their extensive wish list.

It’s still too early to tell precisely how much money Democrats will need to offset the costs of the economic recovery plan President Biden is hoping to advance. But lobbyists are expecting lawmakers to ask drug makers to pony up significant taxpayer savings to help pay for policy on infrastructure and the social safety net.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.